In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats.
about
Phylogeny of Pneumocystis carinii from 18 primate species confirms host specificity and suggests coevolutionActivities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosisCorrelation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein bindingAntifungal activities and cytotoxicity studies of six new azasordarinsAnimal pharmacokinetics and interspecies scaling of sordarin derivatives following intravenous administration.Ploidy of cell-sorted trophic and cystic forms of Pneumocystis carinii.Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.Growth and airborne transmission of cell-sorted life cycle stages of Pneumocystis carinii.SYTO-13, a Viability Marker as a New Tool to Monitor In Vitro Pharmacodynamic Parameters of Anti-Pneumocystis DrugsDiamidines versus Monoamidines as Anti-Pneumocystis Agents: An in Vivo Study.Pneumocystis infection in humans: diagnosis and treatment.Antifungal activity of 10 Guadeloupean plants.Relationship Between Pneumocystis carinii Burden and the Degree of Host Immunosuppression in an Airborne Transmission Experimental Model.Exploring transplacental transmission of Pneumocystis oryctolagi in first-time pregnant and multiparous rabbit does.New agents for the treatment of systemic fungal infections--current status.In vitro and in vivo activity of iclaprim, a diaminopyrimidine compound and potential therapeutic alternative against Pneumocystis pneumonia.
P2860
Q24550815-086043B8-8EE3-46C7-AA5B-ABAFB37D7C96Q28344950-B4EB58A7-3EDE-4722-A099-9EAD0C6F4A55Q28353204-01BDF8C9-C15E-4A39-9F8F-CDE625C0EC75Q28361573-74F7388B-CB03-463F-9292-27C4E3F502A9Q30660609-287DB30F-1A55-427A-9209-A0C2B8967425Q33939254-157606B3-0759-418B-9094-8409B99C27B9Q34335230-E5006A9D-1937-4E3B-8915-C12C4D376542Q35040362-7E57C086-0811-4A14-9E48-96B47D10A229Q35672089-FAEEE852-77B3-43D7-B90C-74A1029E2191Q37277420-FDD0440C-7A7B-4EFE-A2D7-CADE81626F96Q37762544-0CAB1387-8FFF-4B45-B29C-B534F7A01503Q39217990-D0816385-1FBD-44AB-8CE4-014DADBDD667Q40934244-4E7610C7-799A-4C9B-B6E2-C2F89B0B5B49Q44322127-B340CD44-9DE6-4A47-A152-772E646DD69CQ46576615-9A4C113D-B69E-4652-842E-6A364639B943Q47563983-CC8355EE-A3E7-45DC-AD4E-B070F20B5847
P2860
In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
In vitro pharmacodynamic param ...... is carinii isolated from rats.
@ast
In vitro pharmacodynamic param ...... is carinii isolated from rats.
@en
type
label
In vitro pharmacodynamic param ...... is carinii isolated from rats.
@ast
In vitro pharmacodynamic param ...... is carinii isolated from rats.
@en
prefLabel
In vitro pharmacodynamic param ...... is carinii isolated from rats.
@ast
In vitro pharmacodynamic param ...... is carinii isolated from rats.
@en
P2093
P2860
P1476
In vitro pharmacodynamic param ...... tis carinii isolated from rats
@en
P2093
A Martinez
D Gargallo-Viola
E Herreros
L Dujardin
P2860
P304
P356
10.1128/AAC.44.5.1284-1290.2000
P407
P577
2000-05-01T00:00:00Z